Germany: medical and donor requirements in surrogacy and fertility treatment
Start with the proposed treatment, not the diagnosis
The decisive question is not whether a person has a medical indication for a gestational carrier. It is who supplies the egg and sperm, who will carry the pregnancy, where each clinical step occurs, and whether the person giving birth intends to hand the child over permanently. German medical eligibility rules cannot be separated from prohibitions on certain procedures. This guide concerns treatment performed in Germany and medical or donor paperwork relevant to a proposed arrangement; foreign birth recognition and intended-parent eligibility require separate legal analysis.
Section 1(1), nos. 1, 2 and 7, of the Embryo Protection Act (Embryonenschutzgesetz, ESchG) addresses egg transfer, the purpose of fertilisation and artificial fertilisation or embryo transfer involving an intended surrogate. In particular, a practitioner must not artificially inseminate or transfer an embryo to a woman who intends to relinquish the child permanently after birth. The prohibitions do not disappear because participants are relatives, consent, or call the arrangement altruistic. Section 1(3) excludes certain women and intended parents from punishment under specified provisions; that is not a licence for the practitioner to perform the prohibited act.
The lawful and prohibited pathways
Egg donation and sperm donation are not interchangeable. Transferring another woman’s unfertilised egg, and artificially fertilising an egg for a purpose other than bringing about a pregnancy in the woman from whom it came, engage ESchG § 1(1) nos. 1–2. Medically assisted donor-sperm treatment is a different legal category, with a statutory donor register in the covered cases. Neither donor sperm nor the use of a couple’s own gametes turns a prohibited gestational-carrier transfer into lawful treatment. A proposed donation of existing embryos needs separate case-specific legal analysis; it is not a general exemption for surrogacy.
A useful first classification is: (a) the egg provider herself carries the pregnancy using her own egg and, where allowed, partner sperm; (b) she carries with permitted donor sperm; (c) another person supplies the egg; or (d) someone agrees to carry the pregnancy and permanently give the child to intended parents. The third branch raises the egg-donation restrictions; the fourth triggers the surrogacy prohibition for the relevant German medical acts even if no donor gamete is used. A clinic should identify the exact intervention, not merely advertise a broad “donor programme”.
| Proposed arrangement | German legal screening |
|---|---|
| Own egg, self-gestation | Potentially lawful treatment; clinical requirements remain. |
| Donor sperm, self-gestation | Distinct regulated pathway; donor records may apply. |
| Another woman’s egg | Egg-transfer and fertilisation restrictions apply. |
| Permanent handover by gestational carrier | Relevant German assisted-conception or transfer prohibited. |
The Adoption Placement Act (Adoptionsvermittlungsgesetz, AdVermiG) separately defines a surrogate by the agreement to become pregnant or carry an embryo and then hand over the child (§ 13a); § 13c prohibits surrogate-mother intermediation, and § 13d restricts public offers and advertisements. Medical screening, an agency contract, insurance or reimbursement of expenses cannot by themselves undo these statutory restrictions. Whether conduct occurring entirely outside Germany is lawful is a question under the particular foreign law, not an inference from a German clinic’s silence. Under § 13b, even bringing the parties together or identifying an opportunity to conclude such an agreement is intermediation. Section 14b penalises prohibited brokerage, while excluding the surrogate and intended parents from punishment for those particular brokerage offences; that exclusion does not immunise other conduct.
Consent, donor safety and laboratory controls
Where an otherwise lawful assisted-reproduction procedure is contemplated, consent is not a formality. ESchG § 4(1) covers consent by the woman whose egg is fertilised and the man whose sperm is used, and separately the receiving woman’s consent to embryo transfer; it also addresses knowing posthumous fertilisation. Clinics should explain who signs what, at what stage, and how withdrawal or a changed plan will be handled. The presence of signed forms does not cure a prohibited treatment purpose; a risk disclosure and legal authorisation are different things.
Donor suitability and handling requirements have a regulatory layer, not just a clinic brochure. AMWHV § 33 requires written standard procedures for donor assessment and laboratory testing and expressly points to the TPG-Gewebeverordnung. Its gamete-specific § 6 and related annex must be consulted for the actual donor and use category, with the tissue-handling and traceability rules applied where relevant. Test panels, timing and any quarantine exception cannot safely be copied from an unrelated donation category; ask the provider to identify the controlling provision and validated protocol. For heterologous sperm use, § 6(2) requires a physician to assess donor age, health and medical history using a questionnaire followed by a personal interview. Ask whether any additional numerical donor-age limit or optional test is required by a cited rule or is the clinic's own policy. Under TPG-GewV § 6(1), a physician must assess use of the gametes as medically indicated and health protection for the recipient and child must be ensured; for heterologous sperm, § 6(2) additionally requires excluding resulting health risks to others.
In qualifying medically assisted heterologous sperm use, the Sperm Donor Register Act (Samenspenderregistergesetz, SaRegG) governs donor-origin recording. The register has operated since 1 July 2018 and is administered by BfArM. Under § 10, a person conceived this way can seek donor information; from age 16 only that person can exercise the right personally. The register does not cover every private or older arrangement. Therefore “anonymous sperm donor” is not a reliable unqualified description of a covered clinical donation, and record retention and disclosure should be explained before treatment. For a child under 16, a legal representative may apply; the official register retains covered data for 110 years. An application under § 10 requires a birth certificate and relevant identity documents. Access to ancestry information does not, by itself, determine legal parentage.
Genetic tests, clinics and funding
Preimplantation genetic testing is not a general selectable add-on. ESchG § 3a starts from a prohibition and sets narrow circumstances concerning high risk of serious hereditary disease or a serious embryonic condition likely to cause miscarriage or stillbirth. Permitted testing additionally requires information and counselling, written consent from the woman whose egg was used, a favourable assessment by an interdisciplinary ethics commission and an authorised centre with qualified physicians. Screening marketed abroad as routine cannot simply be presumed lawful in a German treatment cycle. Section 3a(5) also states that no physician is obliged to carry out a permitted preimplantation diagnosis; a clinician's refusal is not the same as a statutory ban on every eligible case.
ESchG § 1(1) also regulates embryo numbers and fertilisation practices: nos. 3–5 contain restrictions concerning transfers within a cycle, intratubal gamete transfer and fertilising more eggs than are intended for transfer within a cycle. These provisions cannot be reduced to a slogan that any embryo-production protocol is allowed if only three are transferred. The exact stimulation, fertilisation, culture, freezing and transfer plan needs an individual written explanation from the treating medical team. No universally approved “surrogacy embryo limit” follows from these rules.
An advertised fertility-clinic approval is not a surrogacy licence. SGB V § 121a concerns authorisation for specified providers to perform artificial-fertilisation measures in the statutory-insurance setting; it does not repeal the ESchG or AdVermiG. Ask which named entity and physician will perform collection, fertilisation, storage and transfer, where each step occurs, and under what permission. A website offering donor services is insufficient proof that the particular proposed procedure is legally available.
Public health-insurance funding is a separate filter. Under SGB V § 27a, the ordinary statutory benefit for assisted fertilisation is conditioned, among other things, on medical necessity, adequate chance of success, marriage, use of both spouses’ own eggs and sperm, counselling and an approved plan. Under subsection (3), the covered insured person must have reached 25; a woman who has reached 40 or a man who has reached 50 is outside that benefit, and the fund ordinarily covers 50% of approved costs. These are funding conditions, not universal ages for lawful private treatment and not a way to fund surrogacy.
Documents, overseas plans and safe next steps
A medical file should distinguish the egg provider, sperm provider, person receiving an embryo and intended carers. For lawful treatment, assemble identity and contact records, relevant medical and reproductive history, counselling records, consent versions, donor suitability and laboratory reports where applicable, and embryo or specimen identifiers and custody records. Ask whether the clinic needs translated documents and which reports can legally be shared. No general German statute found here prescribes one single pre-surrogacy certificate package that makes the underlying procedure permissible.
A practical question list for the German provider is: Which step exactly will you do? Who will gestate? Whose egg and sperm are used? Which section authorises this step, and which prohibits any proposed alternative? What donor testing, identity tracing and storage rules will apply? Which consents are required before fertilisation and transfer? Who is licensed, and what happens if a donor or patient fails screening? Insist on written, patient-specific answers rather than interpreting a generic price list as an eligibility decision. For every requested medical or donor criterion, ask whether it comes from binding law, official guidance, professional standards or the clinic's own admission policy.
If a German centre declines a proposed gestational-carrier or egg-donation treatment, first request a precise explanation of the rejected step and its legal or clinical basis. A second specialist opinion may assess a different, genuinely permissible treatment, but it should not be used to disguise the same prohibited procedure under a different label. Legal objections, medical unsuitability, donor-test failure and a clinic’s own policy should be separately documented; each leads to different follow-up action and no single appeal route applies to all refusals. If the dispute is about statutory health-insurance payment rather than treatment legality, ask the insurer for a written decision and information on the applicable challenge procedure; insurance approval would not authorise prohibited treatment.
For a planned treatment abroad, map the chain before paying: country of egg retrieval, fertilisation, embryo storage, transfer and birth; residence and status of every participant; and whether gametes or embryos would cross borders. Obtain foreign counsel’s view on donor and carrier criteria, consent, parentage and the child’s documentation, plus a German assessment of any act contemplated in Germany and subsequent recognition issues. A foreign clinic’s ability to perform a procedure does not create a German right to perform it. Do not assume transport permissions or legal parentage from a medical consent form.
The 2024 German expert commission discussed possible reform of egg donation and altruistic surrogacy; its recommendations were policy proposals, not amendments granting clinics new permission. A later change must be checked against the actual enacted text and commencement date before making a decision. Avoid plans based solely on press coverage, projected bills or the expectation that a future law will cure an action performed now. This distinction is especially important where patients are offered advance packages for a legal regime not yet in force.
In short, begin with four verified facts: gamete sources, intended gestational carrier, location of each intervention and intended post-birth handover. Match those facts to ESchG §§ 1 and 4, AdVermiG §§ 13a–13d, then apply donor-testing, donor-register and specialist-clinic rules only to procedures that remain legally possible. Request a written clinical assessment; seek independent German legal advice on any prohibited or cross-border step before consent, payment or embryo creation. This is a planning framework, not a finding that any individual arrangement is approved.
Official legal sources
- Embryonenschutzgesetz § 1
- Embryonenschutzgesetz § 4
- Adoptionsvermittlungsgesetz § 13a
- Adoptionsvermittlungsgesetz § 13c
- Adoptionsvermittlungsgesetz § 13d
- Samenspenderregistergesetz § 1
- Samenspenderregistergesetz § 10
- TPG-Gewebeverordnung § 6
- AMWHV § 33
- Embryonenschutzgesetz § 3a
- SGB V § 121a
- SGB V § 27a
- BMG: expert commission recommendations, 15 April 2024
- BMG: Samenspenderregister
- Adoptionsvermittlungsgesetz § 13b
- Adoptionsvermittlungsgesetz § 14b
